Despite improvement in pathologic complete response with preoperative chemoradiation, the benefit did not extend to overall ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

The following is a summary of “Dose-response relationships between radiation exposure, bone marrow function as measured by ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

The 2024 half-year financial report has been filed with the French financial market authority (Autorité des marchés financiers). It is available to the public on the Company’s website, ...

Fig 1. Summary of key management of locally advanced rectal cancer guideline recommendations. The following recommendations (strong or conditional) represent reasonable options for patients depending ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial ...

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among ...